P values may lack power: The choice of conduit for above-knee femoropopliteal bypass graft  by Mills, Joseph L.
402
Truth lies within a little and certain compass, but error
is immense.
Henry St. John, Viscount Bolingbroke (Reflections
upon Exile, 1716)
In January 1988, I was called to evaluate a 67-
year-old man (Bob) with an acutely ischemic foot.
The previous year he had undergone a left femoral
to above-knee popliteal artery bypass graft with 6-
mm polytetrafluoroethylene (PTFE) at another hos-
pital. His claudication completely resolved until the
sudden onset of a cool, pale, numb foot several
hours before he went to the emergency department.
I asked the patient if his vein had been inadequate.
Bob replied that his initial surgeon stated that PTFE
would be a good initial choice, saving the vein for
later. After reviewing the options, I proceeded with
a femoral to below-knee popliteal artery bypass graft
with ipsilateral reversed saphenous vein; thrombec-
tomy of the outflow arteries was required to extract
propagated distal thrombus. While preparing this
commentary, I received a Christmas card from Bob.
I contacted him to learn that his vein graft, verified
by duplex scan, remains patent 12 years later. His
saphenous vein was never required for coronary
bypass graft.
The article in this issue entitled “A prospective
randomized trial comparing vein with polytetrafluo-
roethylene in above-knee femoropopliteal bypass
grafts”1 is an attempt to determine the better
approach for a patient such as the one described
above. In this era of evidence-based medicine, the P
value has become the Holy Grail. The authors ran-
domized 136 patients undergoing 151 primary
above-knee femoropopliteal bypass grafts and pre-
sent their 2-year results. The stated aims of the study
were to answer three questions: (1) Is there a differ-
ence in cumulative patency rates between saphenous
vein and PTFE bypass grafts? (2) What are the con-
sequences of bypass graft failure? and (3) If PTFE
was used, is the autologous vein still later available
and usable for more distal procedures? Below, I
review the authors’ data and pertinent literature.
Reluctantly, but of necessity, a brief foray into the
realm of biomedical statistics is performed to evalu-
ate the reliability of the authors’ study design and
conclusions.
IMPORTANT PECULIARITIES OF P
VALUES: IS THERE A DIFFERENCE 
IN CUMULATIVE PATENCY RATES
BETWEEN SAPHENOUS VEIN AND 
PTFE BYPASS GRAFTS?
For infrageniculate popliteal and tibial artery
bypass grafts, vein has clearly been shown to be
superior to prosthetic. The situation is less clear for
above-knee bypass. Surprisingly, I could identify
only two prospective randomized trials comparing
vein versus PTFE that included above-knee
femoropopliteal bypass. Neither study is directly
comparable with the present study of Burger et al,
but both provide useful data for consideration.
Tilanus et al2 prospectively randomized 49 patients
requiring femoropopliteal bypass to vein or PTFE.
The 5-year primary patency rates were 37% for
PTFE versus 70% for saphenous vein (P < .001).
Unfortunately, the study included patients undergo-
ing below-knee (n = 34) and above-knee (n = 15)
bypass grafts, and the size of the latter subsample
was insufficient to allow subgroup analysis.
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INVITED COMMENT
The largest published study comparing saphe-
nous vein with PTFE for infrainguinal bypass was
reported by Veith et al3 in 1986 and included 845
infrainguinal bypass grafts, 176 of which were to the
above-knee popliteal artery. The indication for
surgery was limb salvage in 87% of patients, and 15%
had undergone previous bypass grafting. In contrast,
in the report by Burger et al, all patients were under-
going their first infrainguinal bypass graft, and 79%
were claudicants. Despite these important differ-
ences, the reported results (and lack of a significant
P value) of each study are superficially in agreement,
and if improperly interpreted, will lead the unwary
reader to an “immense error.” In Veith et al’s series,
the 4-year primary patency rates were 61% for vein
and 38% for PTFE (P > .25, not significant). The
critical surveyor of life tables will note that only 14
of the original 167 patients were available for follow-
up at 4 years, too few to generate a meaningful esti-
mate of graft patency. To my knowledge, no subse-
quent report with longer follow-up of these patients
was ever published. This unfortunate situation has
led many to conclude that PTFE and vein for above-
knee bypass grafts are “no different.” Burger et al
inadvertently perpetuate this misconception with the
early publication of their prospective trial: “After
two years, the primary patency of the saphenous vein
was 83%, and of PTFE 67% (P = .065). . . . The use
of PTFE above the knee is a reasonable alternative
for femoropopliteal bypass that is associated with
acceptable short-term patency rates.” The reasons
why lack of a significant P value does not necessarily
imply that the two treatments are no different are
complex and deserve further explanation.
Life table presentation of data is currently the
accepted standard for analysis of graft patency and
mortality. However, as succinctly outlined by
Underwood et al,4 the potential abuses of life table
analysis are substantial. For life table patency curves to
have any real meaning, the follow-up will invariably
need to be considerably longer than the time period
of primary interest to ensure that sufficiently large
numbers of patients are available at a specified point
in time for analysis. Thus, there are two ways of
increasing the span of time over which patency curves
remain reliable. The first is to extend the duration of
the study until a sufficient number of patients have
been followed up for the specific period of interest.
The second is to increase the sample size to an ade-
quate level. The obvious question that needs to be
asked when designing or analyzing a clinical trial is,
what constitutes an adequate sample size?
The probability of detecting a specified differ-
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ence in outcome between treatment groups, if such
a difference is present, is termed the power of the
study. This probability depends not only on a large
sample size, but also on the magnitude of the
expected treatment difference. The literature sug-
gests an expected 5-year primary patency of a PTFE
bypass graft to the above-knee popliteal artery of
50% to 55% (reported range, 38%-65%; the only two
reports exceeding 60% considered only patients with
claudication), in contrast to a likely 5-year primary
patency of 70% to 75% for saphenous vein.
Michaels5 published a detailed review of the choice
of graft material for above-knee popliteal bypass that
included a mathematical model. He estimated that
“assuming there is actually a 20% difference in 5-
year patency, the number of grafts required at 5
years in order to have a 95 per cent chance of show-
ing significance (p < 0.05) is about 160 in each of
the two randomized groups.”
In both Veith et al’s study and Burger et al’s
study, the number of patients entered into the trial is
only approximately half of the number of patients
that would need to be available at 2, 3, or 5 years
(pick one) to generate a 95% chance of detecting a
20% difference in patency. The absence of statistical
significance is thus entirely predictable. Such a
potential statistical error has been termed a Type II
or beta error, or a false-negative conclusion. Small
trials are especially prone to such errors, particularly
if the sample size is inadequate and the power is low.
In addition, if the event rate is low during the peri-
od of analysis, a small trial will generally fail to detect
a substantial outcome difference. Peto et al6
addressed this issue in a landmark paper on clinical
trials. In discussing a hypothetical small clinical trial
of two different cancer treatments, they stated “even
the substantial differences are by no means so sub-
stantial that small trials can readily detect them; it
might be, for example, that when 50% of the control
patients are dead, only 33% of the patients receiving
the new treatment would be expected to have died.
A difference of this magnitude has over 95% chance
of being detected in a trial in which hundreds of
patients are randomized and about 250 of them die,
but only a 25% chance of being detected in a small
trial in which dozens of patients are randomized and
about 25 of them die.” This issue assuredly applies
to the present study of Burger et al. Only 31 events
(graft occlusions) occurred during the entire obser-
vation period, 10 in the vein graft group and 21 in
the PTFE group. With such a low event rate, either
significantly more patients will require randomiza-
tion or much longer follow-up will be necessary to
be reasonably sure that as much as a 20% patency
difference is not present. I am confident that if such
a study of appropriate design and power is ever car-
ried out, no doubt a daunting task, such a difference
(with a significant P value) will result in favor of
vein.
It is also worth emphasizing that further small,
single-center, clinical trials are unlikely to help, and,
in fact, will increase the likelihood not only of false-
negative results, but also of Type I or alpha errors,
that is, false-positive results. As trial size decreases,
the ratio of false-positive conclusions to expected
true positives increases.7 Small clinical trials also ren-
der stratification and subgroup analysis less feasible.
Burger et al report that “none of the risk factors
described in other studies [diabetes, smoking, patent
outflow arteries] have a negative influence on the
patency of the PTFE bypass graft.” The inability to
detect these differences undoubtedly reflects the
unreliability of subgroup analysis when the size of
the subsample is too small.
WHAT ARE THE CONSEQUENCES OF
BYPASS GRAFT FAILURE?
A critical issue for those who advocate PTFE first
for above-knee bypass relates to the consequences of
bypass failure. Twenty-one PTFE grafts occluded,
compared with 10 saphenous vein grafts, using the
authors’ own data. In addition to the twofold occlu-
sion rate, 13 patients required reoperation in the
PTFE group compared with only five in the vein
group, a nearly threefold difference. The authors
conclude “even from this small group of patients
that the use of saphenous vein does result in less
occlusions and less reoperations.” I would not quib-
ble with their conclusion. How do the authors’ data
stack up against other reports of PTFE grafts? In the
oft-quoted UCLA series, it is of interest to examine
the outcome of the 132 patients who were original-
ly operated on for claudication.8 Good-risk claudi-
cants are often considered the best candidates for
preferential above-knee PTFE bypass graft. The
PTFE grafts failed in 28 patients, 20 (15%) of whom
“manifested limb-threatening ischemia as a result of
failure of a bypass that was originally placed for clau-
dication.”8 Experienced surgeons have also noted
the frequency with which the outflow tract seems to
suffer after initial placement of a proximal PTFE
bypass graft. Veith et al presciently noted that “ASV
and PTFE grafts to the popliteal artery failed with
roughly equal frequency up to 18 months; thereafter
the PTFE grafts failed more frequently. This sug-
gests that PTFE grafts, at least in the fe-
moropopliteal position, may be disadvantaged
because they promote progression of distal athero-
sclerosis in some as yet unclarified way.”3 It has also
been suggested that distal embolization from PTFE
femoropopliteal grafts may compromise the outflow
tract. One is forced to conclude that the initial place-
ment of PTFE significantly increases the likelihood
that repeat intervention will be required. Although
repeat leg bypass graft almost never performs as well
as primary leg bypass graft, I would grudgingly
admit that repeat leg bypass graft with good quality
vein outperforms primary leg bypass graft with
PTFE.
IF PTFE WAS USED, IS THE AUTOLO-
GOUS VEIN LATER STILL AVAILABLE
AND USABLE?
The PTFE-first proponents suggest that vein
sparing is an important concept. The present study
did succeed in definitively answering this question:
“None of the patients needed the vein for coronary
bypass graft procedures within the follow-up peri-
od.” Among the 31 occluded bypass grafts in the
series of 151 patients, the vein that was spared was
only used on three occasions.
Other investigators have examined this issue and
reached similar conclusions.9,10 The argument for
saving the vein for later is not very persuasive. In
addition, the issue does not even arise for the
patient’s first bypass graft on the index leg because
the contralateral limb would have saphenous vein
available for use during subsequent coronary artery
bypass or peripheral bypass grafting.
Are there other potential advantages of using
PTFE first that have not been addressed? In most
studies, including the present one, a significantly
shorter operating time is documented for PTFE
bypass graft; time in the operating room was reduced
by 32 minutes (P = .002). However, no study has
demonstrated significantly less major morbidity or
mortality associated with this time savings.
CONCLUSIONS
A proper clinical trial requires enrollment of large
numbers of patients with adequate follow-up to
ensure that the power of the study is sufficient to
detect a difference. Consider that more than 1600
patients were enrolled in the Asymptomatic Carotid
Atherosclerosis Trial to detect a statistically signifi-
cant 55% reduction in stroke risk. Although the
absolute stroke risks for the medical and surgical
groups were virtually identical in the earlier Veteran’s
Administration Asymptomatic Carotid Surgery Trial,
JOURNAL OF VASCULAR SURGERY
404 Mills August 2000
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 2 Mills 405
the latter study of approximately 400 patients failed
to generate a significant P value, a manifest Type II
statistical error. This fatal flaw likely affects both the
1986 Veith et al report as well as the current study
from the Netherlands. As Herodotus wrote in his
Histories: “This is the bitterest pain among men, to
have knowledge but no power.” Repeated publica-
tion of clinical trials lacking statistical power will hin-
der, rather than further, expansion of our clinical
knowledge base.
With respect to PTFE versus vein for primary
above-knee bypass graft, I am fairly certain there is at
least a 20% 5-year patency advantage in favor of vein.
Existing randomized trials are flawed because of the
lack of power resulting in a Type II error. The vein is
rarely needed later. Using PTFE first significantly
increases the likelihood that reintervention will be
required. An initial operating time that is 32 minutes
shorter (P = .002) is insufficient justification for com-
promising long-term results, particularly in patients
with claudication in whom life expectancy is longer.
Use the vein first if it is available. Despite the lack of
a P value, Bob and I are in firm agreement on this
issue.
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